Corbus Pharmaceuticals Holdings Inc (CRBP) Unusual Options Activity Today

Checking CRBP unusual options activity helps you spot when traders are making outsized bets on Corbus Pharmaceuticals Holdings Inc before the broader market catches on. Corbus Pharmaceuticals Holdings Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor CRBP unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching CRBP unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking CRBP unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and CRBP unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.

The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Catalysts rarely arrive without a footprint, and CRBP unusual options activity is often where that footprint shows up first. Our scanner tracks Corbus Pharmaceuticals Holdings Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at CRBP unusual options volume on the call side or chasing put sweeps, Corbus Pharmaceuticals Holdings Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.